Parkside Investments’s BioNTech BNTX Stock Holding History

Parkside Investments’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-500	Closed	-$85K	–	94
2022 Q1	$85K	Buy	+500	New	+$84K	0.02%	102

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Parkside Investments's BNTX Position: Q2 2022 in Review

Parkside Investments sold out of BioNTech (BNTX) in Q2 2022, closing a stake of 500 shares — an estimated $85K sold.

Parkside Investments first reported a position in BNTX in Q1 2022 and held it in 1 quarter. The position peaked at $85K in Q1 2022. 293 funds tracked by Wall St. Rank hold BNTX as of Q2 2022.

Parkside Investments reported no remaining BioNTech position as of Q2 2022 after selling out during the quarter.
Parkside Investments sold 500 BioNTech shares in Q2 2022, an estimated $85K.
Parkside Investments first reported a position in BioNTech in Q1 2022 and held it in 1 quarter.
Parkside Investments's BioNTech position peaked at $85K in Q1 2022.
293 funds tracked by Wall St. Rank held BioNTech as of Q2 2022.

Based on Parkside Investments's 13F filing for Q2 2022, filed 13 Jul 2022.